Education
About Us
Working with TipRanks
Follow Us
Tango Therapeutics (TNGX)
NASDAQ:TNGX
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 42.07M | $ 36.53M | $ 24.86M | $ 37.04M | $ 7.66M |
| Gross Profit | $ 42.07M | $ -78.67M | $ 20.83M | $ 35.08M | $ 6.03M |
| Operating Income | $ -145.59M | $ -114.17M | $ -111.07M | $ -58.19M | $ -52.20M |
| EBITDA | $ -145.59M | $ -111.76M | $ -109.46M | $ -57.29M | $ -51.48M |
| Net Income | $ -130.30M | $ -101.74M | $ -108.18M | $ -58.23M | $ -51.86M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 257.92M | $ 336.88M | $ 366.13M | $ 485.25M | $ 190.32M |
| Total Assets | $ 316.49M | $ 402.57M | $ 436.47M | $ 500.15M | $ 207.25M |
| Total Debt | $ 36.49M | $ 38.92M | $ 41.13M | $ 1.50M | $ 7.88M |
| Net Debt | $ -33.04M | $ -27.46M | $ -18.84M | $ -141.24M | $ -20.50M |
| Total Liabilities | $ 116.97M | $ 149.46M | $ 186.99M | $ 155.41M | $ 168.65M |
| Stockholders' Equity | $ 199.52M | $ 253.11M | $ 249.48M | $ 344.75M | $ 38.60M |
| Cash Flow | |||||
| Free Cash Flow | $ -131.50M | $ -119.51M | $ -116.77M | $ -61.36M | $ 68.97M |
| Operating Cash Flow | $ -131.50M | $ -117.98M | $ -109.08M | $ -59.53M | $ 70.07M |
| Investing Cash Flow | $ 86.13M | $ 41.43M | $ 26.40M | $ -183.43M | $ -145.47M |
| Financing Cash Flow | $ 47.66M | $ 82.41M | $ 1.61M | $ 357.32M | $ 80.88M |